Norges Bank Acquires Shares of 524,804 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Norges Bank acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 524,804 shares of the biotechnology company's stock, valued at approximately $3,947,000. Norges Bank owned 0.25% of BioCryst Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of BCRX. Prudential Financial Inc. raised its stake in BioCryst Pharmaceuticals by 10.2% in the fourth quarter. Prudential Financial Inc. now owns 983,033 shares of the biotechnology company's stock valued at $7,392,000 after purchasing an additional 90,603 shares in the last quarter. Vanguard Group Inc. increased its stake in BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after acquiring an additional 1,583,826 shares during the last quarter. Fox Run Management L.L.C. lifted its stake in BioCryst Pharmaceuticals by 67.4% during the fourth quarter. Fox Run Management L.L.C. now owns 68,040 shares of the biotechnology company's stock worth $512,000 after purchasing an additional 27,406 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $299,000. Finally, Hillsdale Investment Management Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 65,213.3% during the 4th quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company's stock valued at $4,077,000 after buying an additional 541,270 shares in the last quarter. Institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX traded down $0.26 during mid-day trading on Wednesday, reaching $7.15. The stock had a trading volume of 219,270 shares, compared to its average volume of 2,792,232. The company has a fifty day moving average price of $7.91 and a 200 day moving average price of $7.74. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $9.50. The stock has a market cap of $1.49 billion, a PE ratio of -11.78 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. The business's quarterly revenue was up 40.8% compared to the same quarter last year. During the same period last year, the firm earned $0.28 EPS. As a group, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on BCRX. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Royal Bank of Canada restated an "outperform" rating and set a $11.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, April 11th. JMP Securities reissued a "market outperform" rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Evercore ISI upped their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a report on Monday, January 13th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $15.00 target price on shares of BioCryst Pharmaceuticals in a research note on Thursday, April 10th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $15.57.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.